Retinal Disease in Aging Populations: Anti-VEGF Treatment Intervals and Competitive Position | Market Intelligence

Description

List of Tables

Retinal disease is where Japan's aging demography meets one of pharmaceutical history's most successful franchises. Anti-VEGF therapy turned neovascular age-related macular degeneration and diabetic macular edema from blinding inevitabilities into managed chronic conditions, and Japan's elderly population generates treatment demand on a scale matched by few countries. But the Japanese disease mix is distinctive: polypoidal choroidal vasculopathy accounts for a far larger share of neovascular AMD than in Western populations, and that difference shapes drug selection, imaging practice, and trial interpretation in ways that global development programs do not always capture.

The competitive structure is in motion. Faricimab's dual Ang-2/VEGF mechanism and extended-interval positioning, commercialized in Japan by Chugai, contests the aflibercept franchise just as high-dose Eylea HD arrives from the Regeneron-Bayer partnership with Santen as Japan co-promoter. Beneath the originator layer, aflibercept and ranibizumab biosimilars from Samsung Bioepis, Sandoz, and others press on price, while the next generation, sustained-release implants, intravitreal gene therapy, and VEGF-C/D inhibition from Ocular Therapeutix, 4D Molecular Therapeutics, Kodiak, and Opthea, aims at the treatment-burden problem directly. Japan's share of global sales in the newest agents suggests under-penetration, and whether that reflects pricing, interval practice, or channel structure is exactly the question buyers need answered.

This report provides that answer's working parts. It covers the epidemiology and disease-mix structure of retinal disease in Japan's aging population; the treatment landscape molecule by molecule, with treat-and-extend interval practice as practiced in Japanese clinics; the imaging and diagnostic infrastructure, OCT and angiography, that gates treatment decisions; NHI pricing mechanics and biosimilar substitution dynamics; and the pipeline of long-acting and novel-mechanism agents with Japan development status. US, EU5, and China chapters benchmark practice and pricing, including Chengdu Kanghong's conbercept as the China-origin reference point.

The report serves ophthalmology franchise teams at Roche-Chugai, Regeneron-Bayer-Santen, and Novartis; biosimilar sponsors planning entry; retina-clinic chains and hospital departments managing injection volumes; diagnostics vendors; and investors. Interval practice and treatment-burden analysis are treated as commercial variables throughout, not clinical footnotes.

Scope and Coverage

The report covers neovascular AMD including PCV, diabetic macular edema, and retinal vein occlusion across the US, EU5, Japan, and China: treatment landscape, interval practice, imaging infrastructure, NHI pricing and biosimilars, and the long-acting pipeline. Geographic-atrophy therapy is covered as an emerging adjacent category. Surgical retina is outside scope.

Report Highlights

Japanese retinal disease mix and the PCV distinction in nAMD
Molecule-by-molecule landscape: faricimab, aflibercept HD, and legacy agents
Treat-and-extend interval practice in Japanese retina clinics
Biosimilar wave structure and NHI pricing mechanics
Long-acting pipeline: implants, gene therapy, and VEGF-C/D inhibition
Imaging infrastructure and its role in treatment decisions

Product Code: JPH-017

Table of Content

1. Executive Summary

2. Retinal Disease in Aging Populations: Overview and Clinical Background

3. Epidemiology and Patient Population: US, EU5, Japan, and China

4. Current Treatment Landscape and Standard of Care

5. Pipeline and Development Activity

6. Regulatory Pathways: FDA, EMA, PMDA, and NMPA Considerations

7. Reimbursement and Pricing Analysis with a Focus on Japan's NHI System

8. Competitive Landscape and Key Companies

9. Unmet Needs and Commercial Opportunities in Japan

10. Appendix: Methodology and Sources

Companies Mentioned

Roche (CH) - faricimab (Vabysmo) originator
Chugai (JP) - Vabysmo commercialization in Japan
Regeneron (US) - high-dose aflibercept (Eylea HD) and standard aflibercept originator
Bayer (DE) - Eylea ex-US commercialization with Santen as Japan partner
Santen (JP) - Eylea co-promotion in Japan and ophthalmology specialty channel
Novartis (CH) - Beovu legacy and Lucentis history in Japan
Apellis (US) - Syfovre (pegcetacoplan) for geographic atrophy
Kodiak Sciences (US) - tarcocimab long-acting anti-VEGF
Chengdu Kanghong (CN) - conbercept China-origin anti-VEGF
Samsung Bioepis (KR) - aflibercept biosimilar in the Eylea biosimilar wave
Sandoz (CH) - biosimilar anti-VEGF portfolio
Ocular Therapeutix (US) - Axpaxli sustained-release axitinib implant
4D Molecular Therapeutics (US) - 4D-150 intravitreal gene therapy
Opthea (AU) - sozinibercept VEGF-C/D inhibitor

Product Code: JPH-017

List of Tables

Table 1. Retinal disease in aging populations: nAMD, PCV, DME, and RVO frameworks
Table 2. Polypoidal choroidal vasculopathy: definition and the Japanese disease-mix distinction
Table 3. Anti-VEGF and Ang-2/VEGF mechanism taxonomy
Table 4. Milestones in Japanese retinal pharmacotherapy by year
Table 5. Retinal-disease population structure by indication and care setting
Table 6. DME and RVO populations: diabetic and vascular epidemiology frameworks
Table 7. Geographic atrophy as an emerging category in Japan
Table 8. Retina-clinic and hospital-department delivery structure
Table 9. Injection-volume and visit-burden frameworks
Table 10. Current treatment landscape: intravitreal agent positions in Japanese practice
Table 11. Treat-and-extend practice: interval-management protocols in Japanese clinics
Table 12. Imaging-guided retreatment criteria and their operational forms
Table 13. Photodynamic therapy legacy and combination practice in PCV
Table 14. Faricimab (Vabysmo, Roche/Chugai): mechanism and Japan commercialization structure
Table 15. Aflibercept high-dose (Eylea HD, Regeneron/Bayer with Santen): program structure and Japan plan
Table 16. Standard aflibercept (Eylea): franchise position and biosimilar exposure
Table 17. Brolucizumab (Beovu, Novartis) and ranibizumab legacy positions in Japan
Table 18. Aflibercept biosimilars: Samsung Bioepis, Sandoz, and additional sponsors
Table 19. Ranibizumab biosimilar landscape in Japan
Table 20. Conbercept (Chengdu Kanghong): China-origin anti-VEGF reference point
Table 21. Pegcetacoplan (Syfovre, Apellis): geographic-atrophy mechanism and Japan status
Table 22. Tarcocimab (Kodiak Sciences): long-acting anti-VEGF program structure
Table 23. Axpaxli (Ocular Therapeutix): sustained-release axitinib implant program
Table 24. 4D-150 (4D Molecular Therapeutics): intravitreal gene-therapy program
Table 25. Sozinibercept (Opthea): VEGF-C/D inhibition program structure
Table 26. Port-delivery and refillable-implant platform status
Table 27. PMDA pathway for intravitreal agents and long-acting platforms
Table 28. FDA and EMA pathway comparison and label-interval differences
Table 29. NMPA pathway and the Chinese domestic anti-VEGF context
Table 30. NHI pricing structure for intravitreal therapies
Table 31. Biosimilar pricing and substitution mechanics under NHI rules
Table 32. Injection-procedure fee structure and clinic economics
Table 33. Imaging-equipment reimbursement: OCT and angiography
Table 34. US and EU5 payment comparison for intravitreal therapy
Table 35. China payment environment for anti-VEGF treatment
Table 36. Roche and Chugai: faricimab franchise organization in Japan
Table 37. Regeneron, Bayer, and Santen: aflibercept partnership structure
Table 38. Novartis: legacy ophthalmology positions in Japan
Table 39. Biosimilar sponsors: Japan entry structures and channel choices
Table 40. Apellis, Kodiak, Ocular Therapeutix, 4DMT, and Opthea: pipeline-sponsor profiles
Table 41. Chengdu Kanghong and the China-origin competitive context
Table 42. Ophthalmology-clinic chain landscape and injection-capacity structure
Table 43. Unmet needs: treatment burden, undertreatment, and PCV-specific questions
Table 44. Interval-extension practice variation and its commercial implications
Table 45. Biosimilar adoption pathways in Japanese ophthalmology
Table 46. Long-acting platform scenarios and their channel requirements
Table 47. Imaging-infrastructure investment opportunities
Table 48. Policy agenda: pricing review points and biosimilar promotion measures
Table 49. Report methodology: label and guideline analysis, channel research, and interview base
Table 50. Glossary of indications, mechanisms, and device terms

List of Figures

Figure 1. Retinal disease framework map: nAMD, PCV, DME, and RVO
Figure 2. PCV pathology schematic and the Japanese distinction
Figure 3. Anti-VEGF and Ang-2/VEGF mechanism map
Figure 4. Japanese retinal pharmacotherapy timeline
Figure 5. Retinal-disease population structure framework
Figure 6. DME and RVO epidemiology framework diagram
Figure 7. Geographic-atrophy category map
Figure 8. Retina-care delivery structure in Japan
Figure 9. Injection-volume and visit-burden schematic
Figure 10. Intravitreal agent position map in Japanese practice
Figure 11. Treat-and-extend protocol flow
Figure 12. Imaging-guided retreatment decision structure
Figure 13. PDT legacy and PCV combination practice diagram
Figure 14. Faricimab mechanism and Japan structure map
Figure 15. Eylea HD program structure and Japan plan diagram
Figure 16. Standard aflibercept franchise position map
Figure 17. Brolucizumab and ranibizumab legacy positions
Figure 18. Aflibercept biosimilar sponsor map
Figure 19. Ranibizumab biosimilar landscape
Figure 20. Conbercept China-origin reference diagram
Figure 21. Pegcetacoplan mechanism and Japan status map
Figure 22. Tarcocimab program structure schematic
Figure 23. Axpaxli implant program diagram
Figure 24. 4D-150 gene-therapy program schematic
Figure 25. Sozinibercept program structure map
Figure 26. Port-delivery platform status diagram
Figure 27. PMDA pathway flow for intravitreal agents
Figure 28. FDA and EMA label comparison map
Figure 29. NMPA pathway and domestic context diagram
Figure 30. NHI pricing structure for intravitreal therapies
Figure 31. Biosimilar substitution mechanics flow
Figure 32. Injection-fee structure and clinic economics diagram
Figure 33. Imaging reimbursement decision points
Figure 34. US and EU5 payment comparison map
Figure 35. China payment environment diagram
Figure 36. Roche-Chugai franchise organization map
Figure 37. Regeneron-Bayer-Santen partnership structure
Figure 38. Novartis legacy position diagram
Figure 39. Biosimilar sponsor entry structure map
Figure 40. Pipeline-sponsor profile map
Figure 41. China-origin competitive context diagram
Figure 42. Clinic-chain landscape and capacity structure
Figure 43. Unmet-need map: burden, undertreatment, PCV questions
Figure 44. Interval-practice variation framework
Figure 45. Biosimilar adoption pathway schematic
Figure 46. Long-acting platform scenario map
Figure 47. Imaging-infrastructure opportunity map
Figure 48. Policy lever map: pricing and biosimilar promotion
Figure 49. Methodology flow: labels, guidelines, channel research
Figure 50. Data cut-off and update cadence schematic

Retinal Disease in Aging Populations: Anti-VEGF Treatment Intervals and Competitive Position | Market Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. Retinal Disease in Aging Populations: Overview and Clinical Background

3. Epidemiology and Patient Population: US, EU5, Japan, and China

4. Current Treatment Landscape and Standard of Care

5. Pipeline and Development Activity

6. Regulatory Pathways: FDA, EMA, PMDA, and NMPA Considerations

7. Reimbursement and Pricing Analysis with a Focus on Japan's NHI System

8. Competitive Landscape and Key Companies

9. Unmet Needs and Commercial Opportunities in Japan

10. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures